Metastatic Breast Cancer - Pipeline Review, H2 2012


#156230

21pages

Global Markets Direct

$ 2500

In Stock

 

Global Markets Directs, 'Metastatic Breast Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. 

 

It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. Metastatic Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Metastatic Breast Cancer.
  • A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Breast Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Metastatic Breast Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Metastatic Breast Cancer 6
Metastatic Breast Cancer Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Metastatic Breast Cancer Therapeutics - Products under Development by Companies 12
Companies Involved in Metastatic Breast Cancer Therapeutics Development 13
Abbott Laboratories 13
Mesoblast Ltd 14
Yuhan Corporation 15
KOLON LIFE SCIENCE INC. 16
TissueGene, Inc. 17
Stem Cell Assurance, Inc. 18
Metastatic Breast Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19


Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21


Number of Products Under Development for Metastatic Breast Cancer, H2 2012 6
Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Comparative Analysis by Mid Clinical Stage Development, H2 2012 9
Comparative Analysis by Early Clinical Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Abbott Laboratories, H2 2012 13
Mesoblast Ltd, H2 2012 14
Yuhan Corporation, H2 2012 15
KOLON LIFE SCIENCE INC., H2 2012 16
TissueGene, Inc., H2 2012 17
Stem Cell Assurance, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19


Number of Products under Development for Metastatic Breast Cancer, H2 2012 6
Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Mid Clinical Stage Products, H2 2012 9
Early Clinical Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19